The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
Impetigo R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Impetigo Pipeline Overview The Q4 Impetigo pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Impet...
October 2020
51 pages
Influenza B Infections R&D Pipeline Analysis Report, Q4 2020
US$ 2,199.00
Influenza B Infections Pipeline Overview The Q4 Influenza B Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs...
October 2020
162 pages
Insulin Resistance R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Insulin Resistance Pipeline Overview The Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs und...
October 2020
53 pages
Japanese Encephalitis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Japanese Encephalitis Pipeline Overview The Q4 Japanese Encephalitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
51 pages
Kaposi Sarcoma R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Kaposi Sarcoma Pipeline Overview The Q4 Kaposi Sarcoma pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
72 pages
Lassa Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Lassa Fever Pipeline Overview The Q4 Lassa Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
65 pages
Lyme Disease R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Lyme Disease Pipeline Overview The Q4 Lyme Disease pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
68 pages
Measles R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Measles Pipeline Overview The Q4 Measles pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Measles...
October 2020
54 pages
Meningitis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Meningitis Pipeline Overview The Q4 Meningitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for M...
October 2020
64 pages
Mumps R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Mumps Pipeline Overview The Q4 Mumps pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Mumps, prov...
October 2020
40 pages
Myasthenia Gravis R&D Pipeline Analysis Report, Q4 2020
US$ 2,199.00
Myasthenia Gravis Pipeline Overview The Q4 Myasthenia Gravis pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under develop...
October 2020
162 pages
Osteomyelitis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Osteomyelitis Pipeline Overview The Q4 Osteomyelitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...
October 2020
52 pages
Peanut Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Peanut Allergy Pipeline Overview The Q4 Peanut Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
134 pages
Pemphigus Vulgaris R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Pemphigus Vulgaris Pipeline Overview The Q4 Pemphigus Vulgaris pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under devel...
October 2020
72 pages
Phenylketonuria (PKU) R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Phenylketonuria (PKU) Pipeline Overview The Q4 Phenylketonuria (PKU) pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of dru...
October 2020
81 pages
Plague R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Plague Pipeline Overview The Q4 Plague pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Plague, p...
October 2020
52 pages
Polio (Poliomyelitis) R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Polio (Poliomyelitis) Pipeline Overview The Q4 Polio (Poliomyelitis) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
101 pages
Pompe Disease R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Pompe Disease Pipeline Overview The Q4 Pompe Disease pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under develop...
October 2020
101 pages
Pyelonephritis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Pyelonephritis Pipeline Overview The Q4 Pyelonephritis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
81 pages
Rabies R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Rabies Pipeline Overview The Q4 Rabies pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Rabies, p...
October 2020
97 pages
Rhinovirus Infections R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Rhinovirus Infections Pipeline Overview The Q4 Rhinovirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
71 pages
Rotavirus Infections R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Rotavirus Infections Pipeline Overview The Q4 Rotavirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs und...
October 2020
58 pages
Schistosomiasis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Schistosomiasis Pipeline Overview The Q4 Schistosomiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under develop...
October 2020
48 pages
Sjogren Syndrome R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Sjogren Syndrome Pipeline Overview The Q4 Sjogren Syndrome pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
147 pages
Smallpox R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Smallpox Pipeline Overview The Q4 Smallpox pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Small...
October 2020
64 pages
Tetanus R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Tetanus Pipeline Overview The Q4 Tetanus pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Tetanus...
October 2020
132 pages
